Results from Australian paediatric study accepted for publication in peer-reviewed
journal. A publication titled, “A prospective multicentre study testing the diagnostic accuracy
of an automated cough sound centred analytic system for the identification of common
respiratory disorders in children” has been accepted for publication by the peer-reviewed
medical journal Respiratory Research. The publication summarises results from the
Australian Breathe Easy pivotal study, a prospective, multi-centre study which compared the
diagnosis of paediatric respiratory illness using ResApp’s cough-based algorithms to clinical
diagnosis. The study analysed 585 subjects aged 29 days to 12 years of age. The positive
percent and negative percent agreement values between the algorithms and the clinical
reference were as follows: asthma (97%, 91%); pneumonia (87%, 85%); lower respiratory tract
disease (83%, 82%); croup (88%, 86%); bronchiolitis (84%, 81%). Data from ResApp’s
SMARTCOUGH-C-2 paediatric pivotal study will also be presented at the American Thoracic
Society (ATS) 2019 International Conference, May 17-22nd in Dallas, Texas.
- Forums
- ASX - By Stock
- RAP
- Ann: Quarterly Update and Appendix 4C
Ann: Quarterly Update and Appendix 4C, page-3
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 154 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online